α-Galactosidase Aggregation Is a Determinant of Pharmacological Chaperone Efficacy on Fabry Disease Mutants
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
α-Galactosidase Aggregation Is a Determinant of Pharmacological Chaperone Efficacy on Fabry Disease Mutants
Authors
Keywords
-
Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 287, Issue 34, Pages 28386-28397
Publisher
American Society for Biochemistry & Molecular Biology (ASBMB)
Online
2012-07-07
DOI
10.1074/jbc.m112.351056
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SNPeffect 4.0: on-line prediction of molecular and structural effects of protein-coding variants
- (2011) G. De Baets et al. NUCLEIC ACIDS RESEARCH
- Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests
- (2011) Giuseppina Andreotti et al. Orphanet Journal of Rare Diseases
- Chemical and/or biological therapeutic strategies to ameliorate protein misfolding diseases
- (2010) Derrick Sek Tong Ong et al. CURRENT OPINION IN CELL BIOLOGY
- Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study
- (2010) Giuseppina Andreotti et al. Orphanet Journal of Rare Diseases
- Biological and Chemical Approaches to Diseases of Proteostasis Deficiency
- (2009) Evan T. Powers et al. Annual Review of Biochemistry
- Effects of pH and Iminosugar Pharmacological Chaperones on Lysosomal Glycosidase Structure and Stability
- (2009) Raquel L. Lieberman et al. BIOCHEMISTRY
- Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics
- (2009) Giancarlo Parenti EMBO Molecular Medicine
- Protein sequences encode safeguards against aggregation
- (2009) Joke Reumers et al. HUMAN MUTATION
- Structural modeling of mutant α-glucosidases resulting in a processing/transport defect in Pompe disease
- (2009) Kanako Sugawara et al. JOURNAL OF HUMAN GENETICS
- The pharmacological chaperone 1-deoxygalactonojirimycin increases α-galactosidase A levels in Fabry patient cell lines
- (2009) E. R. Benjamin et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Fabry disease
- (2009) Raphael Schiffmann PHARMACOLOGY & THERAPEUTICS
- Rescue of mutant α-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes
- (2008) Ryoji Hamanaka et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Chemical and Biological Approaches Synergize to Ameliorate Protein-Folding Diseases
- (2008) Ting-Wei Mu et al. CELL
- Annotating single amino acid polymorphisms in the UniProt/Swiss-Prot knowledgebase
- (2008) Yum L. Yip et al. HUMAN MUTATION
- Structural characterization of mutant α-galactosidases causing Fabry disease
- (2008) Kanako Sugawara et al. JOURNAL OF HUMAN GENETICS
- Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone
- (2008) Sang H. Shin et al. Pharmacogenetics and Genomics
- Quantifying information transfer by protein domains: Analysis of the Fyn SH2 domain structure
- (2008) Tom Lenaerts et al. BMC STRUCTURAL BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now